Project Grant R21AI203106
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Lafayette, IN, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $442,500 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antimicrobial agents derived from aapeptide biomaterials targeting drug-resistant bacterial infections. The research addresses antimicrobial resistance identified by the World Health Organization as a major twenty-first-century threat. Purdue will develop small-molecule scorpion-like amphipathic...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Purdue University $239,023 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop covalent phosphatidylinositol 4-kinase (PI4K) inhibitors targeting malaria parasites. The project executes hit-to-lead optimization of high-priority molecular scaffolds against Plasmodium species that inhibit...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $229,127 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop CDC14 phosphatase inhibitors as novel antifungal agents. The project addresses invasive fungal diseases, which contribute to approximately 3.8 million deaths annually, particularly among immunocompromised populations. The work optimizes chemical compounds that selectively inhibit CDC14, a fungal protein...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $498,154 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into signaling mechanisms governing chimeric antigen receptor T cell activation. The research addresses a critical gap in understanding how CAR T cells recognize and eliminate target cells while avoiding off-target activation and collateral damage. CAR T cells express artificial receptors...
- The National Institute of Allergy and Infectious Diseases awarded Prokaryotics Incorporated $299,697 on September 19, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a mechanistically novel antifungal agent targeting cell wall β-1,3-D-glucan biosynthesis with broad-spectrum activity against pathogenic yeasts and molds, including echinocandin-resistant strains. The project runs through February 28, 2027, with performance in Union, New Jersey. Phase 1...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $599,327 to Microbiotix, Inc. on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel benzyl-piperidine antifungal agents targeting intractable mucormycosis infections caused by drug-resistant Mucorales fungi. The project focuses on chemical optimization of a benzyl-piperidine series to improve drug-like properties and...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $240,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop new drug leads targeting F1F0 ATP synthase inhibitors for treatment of primary amoebic meningoencephalitis caused by Naegleria fowleri. The research identified two pure compounds derived from marine microbial metabolites that exhibit nanomolar potency against multiple N. fowleri...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $796,976 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a once-daily ocular nanoformulation of BX795, a non-nucleoside antiviral drug for herpes simplex virus keratitis therapy. HSV-1 keratitis causes corneal blindness globally, and current nucleoside antiherpetic treatments administered orally or topically prove insufficient, with emerging...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin – Madison $791,200 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize novel heterocyclic inhibitors against Naegleria fowleri and validate their molecular targets. The award supports development of drug candidates to treat N. fowleri meningoencephalitis, a parasitic brain infection with greater than 97 percent mortality for which no FDA-approved...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $440,908 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify inhibitors of bacterial peptidyl-tRNA hydrolase (PTH). The recipient will synthesize and optimize derivatives of PTH inhibitor compounds with sub-micromolar IC50 values to enhance their activity against Klebsiella pneumoniae PTH and improve cellular uptake. The work includes expanding...